Acrivon Therapeutics Reports Positive Endometrial Cancer Data From Ongoing Acr-368 Registrational Intent Phase 2 Study at Esmo, Advancement of Acr-2316 Into Clinic Ahead of Timelines, and Progress on Its AP3 Interactome for Proprietary Data Analysis
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.